PFS and OS by 3L treatment in the axi-cel arm since 3L treatment initiation. ∗Six of these 8 patients received subsequent SCT in any line. This analysis followed the statistical analysis plan for the ZUMA-7 primary event-free survival analysis,⁶ whereby patients who received subsequent SCT while in response from 3L axi-cel were censored at time of SCT. Because there were no available data for this subgroup at 12 months, the PFS rate is not evaluable. Kaplan-Meier estimates were calculated from 3L treatment initiation. No., number.